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Background: The 2019 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report made recommen-
dations for the assessment, initial and subsequent treatment chronic obstructive pulmonary disease (COPD)
based on biomarkers, including blood eosinophil counts.
Methods: We evaluated the distribution of UK COPD patients initiating maintenance therapy and established
patients by GOLD group, the prevalence of comorbidities and appropriateness of therapy using electronic
patient records from the Optimum Patient Care Research Database (OPCRD). Changes in effective GOLD
group, therapy and exacerbation rates over the next 2 years were analysed.
Findings: 11,409 established COPD patients and 699 starting therapy were studied. 44¢3%, 25¢7%, 13¢8% &
16¢2% of established COPD patients and 45¢2%, 28¢5%, 15¢7% & 10¢6% initiating therapy were in GOLD groups
A, B, C & D respectively.
The overall proportion in each GOLD group was similar after 2 years but there was substantial movement of
patients between groups. Diabetes and cardiovascular disease were the most common comorbidities in all
groups in both cohorts.
LAMA monotherapy was the commonest initial therapy in all GOLD groups. In both cohorts there was over-
treatment with escalation, de-escalation or switching in nearly 50% during follow-up.
In both cohorts, exacerbation rates were highest in group D and appeared higher in over-treated patients.
Interpretation: Most patients are not at risk of exacerbations and co-morbidities are common. Many patients
change effective GOLD group and therapy over time. Prescribing is not in accordance with guideline recom-
mendations and many patients still appear over treated.
© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)Keywords:
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In 2017 the Global Obstructive Lung Disease initiative (GOLD) pub-
lished new recommendations on the assessment of COPD [1] separating
the degree of spirometric impairment from the four GOLD groups A to D
which classify patients on the basis of the level of symptoms and the risk
of exacerbations, assessed now solely by the number of exacerbations in
the previous year. The 2019 GOLD Report clariﬁes previous recommen-
dations that the groups are solely used as the basis for the choice of initial
therapy [2]. Many clinicians had interpreted the recommendations as if
they applied to patients at any stage of their management, although this
was not what was stated or intended and previous studies on the appro-
priateness of therapy have studied populations that were already receiv-
ing maintenance therapy rather than examining initial treatment
choices [36].These studies have shown a higher use of ICS and under-prescrip-
tion of bronchodilators than expected based on the recommenda-
tions [3,711]; however, their interpretation is limited by the fact
some patients may have responded well to therapy and reduced the
level of their symptoms, had fewer exacerbations or both, resulting
in erroneous conclusions about the appropriateness of their therapy.
We applied the 2017 assessment scheme to patients with COPD
under the care of General Practitioners in the United Kingdom (UK) to
determine the distribution of patients and whether it identiﬁed groups
with different outcomes such as exacerbation rate. As in studies of the
distribution of patients according to previous GOLD recommendations,
we examined the distribution into the four groups among established
patients with COPD (cohort 1), but importantly we have also investi-
gated the distribution of patients initiating maintenance therapy
(cohort 2), who are the true target of the GOLD assessment scheme.
We also examined the distribution of spirometric impairment and
comorbidities among patients in each group in both established
patients and those initiating maintenance therapy. We examined the
Research in Context
Evidence Before This Study
In 2019 GOLD published updated recommendations on the
management of COPD focussing on the initial and subsequent
use of inhaled therapy. Previous studies have compared the use
of therapy in practice with previous GOLD recommendations
and have examined outcomes such as exacerbation rates in
people categorised into the four GOLD groups A to D. However,
these studies have almost exclusively been in people already
on maintenance therapy when it is impossible to determine if
therapy is appropriate or not as it may have changed the level
of symptoms of exacerbation rates leading to false conclusions.
Added Value of This Study
To our knowledge, this is the ﬁrst study to compare pre-
scribing patterns in a large cohort of unselected patients with
COPD to the GOLD 2019 recommendations for initial and subse-
quent therapy whilst also examining the changes in breathless-
ness and exacerbation rates over time and their relationship to
the appropriateness of the therapy. Many patients in groups A
& B who are at low risk of exacerbations appeared overtreated,
particularly with inhaled corticosteroids, but the exacerbation
rates in these patients were higher than those appropriately
treated suggesting additional clinical features may have inﬂu-
enced the prescription of therapy. The study also shows for the
ﬁrst time in a large primary care cohort the marked changes in
patients' level of symptoms and number of exacerbations over
time leading to movement between GOLD groups.
Implications of All the Available Evidence
The GOLD assessment scheme does predict patients at
higher risk of exacerbation and patients' level of symptoms
and number of exacerbations changes over time, either spon-
taneously or as a result of therapy. GOLD groups should not be
used to assess the appropriateness of established therapy 
this should be based on the level of continuing breathlessness
and number of exacerbations, taking into account the blood
eosinophil count. Compared to the GOLD recommendations
there is signiﬁcant overtreatment, but other factors may guide
individual treatment choices and in some cases these may be
appropriate. Further work to characterise these would assist
the development of future treatment recommendations.
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tenance therapy, and the appropriateness of the maintenance inhaled
therapy in the established COPD patients with reference to the GOLD
2019 recommendations. We determined whether patients appeared to
have changed groups, what the annual exacerbation rates were and
whether these were related to the appropriateness of therapy.
2. Methods
2.1. Data Source
A population-based cohort study was carried out using the continu-
ous electronic health record database, Optimum Patient Care Research
Database (OPCRD) which contains anonymised routine, patient-level
diagnostic, clinical and prescribing information on approximately
5¢8 million patients from over 700 primary care centres across the UK
(http://opcrd.co.uk/). OPCRD has received a favourable opinion fromthe NHS Health Research Authority for anonymous research use (REC
reference: 15/EM/0150). Governance is provided and study protocol
was approved by the Anonymised Data Ethics and Protocols Transpar-
ency (ADEPT) committee (ADEPT0918), an independent body of
experts and regulators commissioned by the Respiratory Effectiveness
Group (REG, http://www.effectivenessevaluation.org/). The study pro-
tocol was registered with the European Union electronic Register of
Post-Authorization studies (EUPAS25136).
2.2. Study Population
All patients with established COPD (had at least one diagnostic
Read code (Quality Outcomes Framework (QOF) deﬁned) for COPD
before the index date (ID)) who were continuously registered at a gen-
eral practice between January 1, 2013 and December 31, 2016 were
eligible for inclusion in the analysis. To be coded as having COPD
patients had to have had spirometry. Cohort 1 comprised patients
with established COPD, irrespective of maintenance treatment for
COPD. In this cohort the ID was deﬁned as January 1, 2014. Cohort 2
comprised established COPD patients who initiated maintenance
treatment in the year 2014. The date of initiating maintenance treat-
ment for COPD was deﬁned as the ID, the date at which the patient
received their ﬁrst prescription of long-acting beta agonists (LABA),
long-acting muscarinic antagonists (LAMA), inhaled corticosteroids
(ICS), or combination therapies of LABA, LAMA and ICS (LAMA/LABA,
ICS/LABA, ICS/LAMA, LABA/LAMA/ICS) in the year 2014. Patients in
cohort 2 were not included in cohort 1. For further details of the data
requirements and data extracted from OPCRD see the appendix.
The primary outcome in each cohort was the change of GOLD groups
over a 2-year period. The classiﬁcation of each patient by GOLD group in
2016was comparedwith their GOLD group in 2014. Additional outcomes
were the appropriateness of the therapy with reference to GOLD 2019 in
patients in cohort 1 based on their breathlessness (mMRC score), exacer-
bation frequency and blood eosinophil count (for details of the criteria
used see appendix, table S1), and the appropriateness of the initial ther-
apy in cohort 2 (see appendix, table S2). Patients were classiﬁed as
under-, appropriately or over-treated on the ID. The number of patients
who appeared over-treated who had a diagnosis of current asthma was
also calculated. Patients were further categorised as having escalation,
de-escalation, switching or no change in their therapy between 2014 and
2016 (for details of the criteria used see appendix, table S3).
In both cohorts the number of exacerbations and pneumonia
events for each patient were calculated over 2-year follow-up. Exac-
erbations were identiﬁed using the criteria described in the appendix.
Pneumonia events were deﬁned by all relevant diagnostic read codes.
Read codes that were recorded within 28 days of each other were
considered to belong to the same pneumonia event.
2.3. Statistical Analysis
Kappa statistics were used to examine changes in GOLD groups
over the 2-year period, and were interpreted according to the classiﬁ-
cation system proposed by Landis and Koch [12]. We evaluated the
relationship between GOLD group and exacerbation rates within each
cohort, using a negative binomial regression model allowing over-dis-
persion with GOLD group A as the reference group. A subgroup analy-
sis based on appropriateness of maintenance therapy (under-,
appropriate and over-treatment) according to GOLD 2019 was also
conducted for exacerbations. Since the majority of patients had no
pneumonia during follow-up, a zero-inﬂated negative binomial regres-
sion model was used to examine the association between the GOLD
groups and pneumonia, and ﬁndings were reported as rate ratio (RR)s
(95% CIs). The change in maintenance treatment over two years were
compared between the GOLD groups within cohort 2, using a multi-
nominal logistic regression model with ﬁndings reported as relative
risk ratios (RRRs) with the corresponding 95% CIs. In the unconditional
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founders did not change the association. Potential confounders were
included in the ﬁnal model if they independently changed the esti-
mated effect for the GOLD groups by 10%. Potential confounders, as
measured at baseline, included smoking and inhaled corticosteroid
use. Because of the low percentage of missing data in the study (see
Tables 1 and 2), no imputation method was used. All analyses were
conducted using SAS V9.3 (SAS Institute Inc., Cary, N.C.).
2.4. Complementary Analysis
We expected the prevalence of comorbidities to be higher in
patients with established COPD (cohort 1) compared with those initi-
ating maintenance therapy (cohort 2); however, this was not the case
in our preliminary analysis [13]. We therefore examined the preva-
lence of comorbid conditions in a general population to determine
whether the overall prevalence of comorbidities was higher in
patients with established COPD, reﬂecting the systemic effects of the
disease, including at an early stage, or whether it is simply a feature
of an older population group (for details see appendix).
3. Results
11,409 patients were identiﬁed as established COPD patients
forming cohort 1 and 699 patients started maintenance therapy for
the ﬁrst time during 2014 forming cohort 2 (Fig. 1). Among estab-
lished patients 44¢3% had the characteristics of GOLD group A, 25¢7%
group B, 13¢8% group C and 16¢2% group D (Table 1). In patients initi-
ating maintenance therapy, 45¢2% were in GOLD group A, 28¢5% in
group B, 15¢7% in group C and 10¢6% in group D (Table 2).Table 1
Baseline characteristics of established COPD patients.
Baseline characteristics Group A Group B
N = 5053 N = 2938
% of patients in group 44¢3 25¢7
Mean age (y)(SD) 70¢4 (9¢5) 72¢1 (9¢6)
Men % 56¢9 55¢0
Non-missing, n (%) 5049 (99¢9) 2937 (99¢9
Mean BMI (SD) 27¢3 (5¢3) 28¢7 (6¢7)
Non-missing, n (%) 5026 (99¢5) 2925 (99¢6
Current smokers n (%) 1571 (31¢3) 906 (31¢0
Ex-smokers n (%) 2886 (57¢4) 1713 (58¢6
Non-smokers n (%) 569 (11¢3) 306 (10¢4
Asthma (%) 877 (17¢4) 522 (17¢8
Non-missing, n (%) 5017 (99¢3) 2915 (99¢2
Mean FEV1% predicted(SD) 67¢5 (21¢3) 59¢3 (22¢5
Gold 1: 80% 1268 (26¢2) 443 (15¢7
Gold 2: 5079% 2697 (55¢8) 1443 (51¢3
Gold 3: 3049% 697 (14¢4) 701 (24¢9
Gold 4: <30% 174 (3¢6) 228 (8¢1)
Mean exacerbations/y (SD) 0¢3 (0¢5) 0¢4 (0¢5)
Exacerbations/y in previous year 3495 (69¢2) 1819 (61¢9
1558 (30¢8) 1119 (38¢1
0 (0) 0 (0)
Mean mMRC (SD) 0¢7 (0¢5) 2¢4 (0¢6)
Non-missing, n (%) 4675 (92¢5) 2802 (95¢4
Mean Eosinophil count (109/L) (SD) 0¢2 (0¢2) 0¢2 (0¢2)
Eosinophil count< 0¢30 109/L 3152 (67¢4) 1911 (68¢2
Eosinophil count 0¢30 109/L 1523 (32¢6) 891 (31¢8
Maintenance therapy in the year before index date, n (%)
None 796 (15¢8) 190 (6¢5)
LAMA only 1259 (24¢9) 764 (26¢0
LABA only 215 (4¢2) 86 (2¢9)
ICS only 537 (10¢6) 163 (5¢6)
ICS + LABA 1448 (28¢7) 882 (30¢0
ICS + LAMA 51 (1¢0) 39 (1¢3)
LAMA + LABA 55 (1¢1) 44 (1¢5)
ICS + LABA + LAMA 692 (13¢7) 770 (26¢23.1. Baseline Characteristics
The mean age of established patients was approximately 70 years,
with patients in group B being a little older than those in the other
groups (Table 1). There was more variation in the age of patients start-
ing maintenance therapy with those in groups B & D being slightly older
(Table 2). In established patients, men outnumberedwomen in groups A
& B but the numbers were approximately equal in groups C & D,
whereas men accounted for approximately 60% of patients in all groups
initiating therapy. The prevalence of current smoking was about 30% in
established COPD patients with no difference between groups, but it
was higher in patients initiating therapy (at 4547%). Approximately
17% of established patients in groups A & B and 2224% in groups C & D
had a diagnosis of current asthma (Table 1). A lower proportion of
patients in each GOLD group initiating therapy had asthma (Table 2).
The distribution of FEV1 impairment was similar among established
patients (Table 1), although there weremore GOLD stage 3 and 4 patients
in group D. In patients initiating maintenance therapy there were very
few GOLD stage 4 patients in group A and more stage 3 and 4 patients in
groups C and D. The mean mMRC score for patients initiating therapy in
groups A and C was 0¢70¢8 and 2¢32¢5 in patients in groups B & D.
There was no difference between mMRC scores in established patients in
groups A and C or between groups B and D, but the mean scores were
higher in established COPD patients (cohort 1) in groups B & D compared
with those initiating therapy (cohort 2) (Tables 1 & 2).
The mean exacerbation rates in the 12months prior to ID were
similar in both cohorts, with mean rates in patients in groups A and B
between 0¢30¢4 per year. Over 60% of patients in these groups had
not had an exacerbation in the previous year. In groups C and D of
both cohorts the mean rate was approximately 2¢63¢3 per year.Group C Group D Overall
N = 1574 N = 1844 N = 11409
13¢8 16¢2 
69¢9 (9¢6) 70¢4 (9¢5) 70¢8 (9¢6)
51¢9 47¢9 54¢3
) 1574 (100) 1842 (99¢9) 11,402 (99¢9)
27¢3 (5¢8) 28¢3 (6¢8) 27¢8 (6¢0)
) 1572 (99¢9) 1837 (99¢6) 11,360 (99¢6)
) 534 (34¢0) 572 (31¢1) 3583 (31¢5)
) 847 (53¢9) 1095 (59¢6) 6541 (57¢6)
) 191 (12¢2) 170 (9¢3) 1236 (10¢9)
) 379 (24¢1) 409 (22¢2) 2187 (19¢2)
) 1558 (98¢9) 1834 (99¢5) 11,324 (99¢3)
) 64¢2 (32¢3) 55¢4 (22¢1) 63¢0 (24¢0)
) 312 (20¢8) 238 (13¢5) 2261 (20¢7)
) 781 (52¢1) 791 (44¢8) 5712 (52¢3)
) 313 (20¢9) 532 (30¢1) 2243 (20¢6)
93 (6¢2) 206 (11¢6) 701 (6¢4)
2¢8 (1¢3) 3¢3 (1¢8) 1¢2 (1¢6)
) 0 (0) 0 (0) 5314 (46¢6)
) 0 (0) 0 (0) 2677 (23¢5)
1574 (100¢0) 1844 (100¢0) 3418 (29¢9)
0¢8 (0¢4) 2¢5 (0¢6) 1¢4 (1¢0)
) 1506 (95¢7) 1776 (96¢3) 10,759 (94¢3)
0¢3 (0¢3) 0¢3 (0¢2) 0¢3 (0¢2)
) 986 (65¢5) 1136 (64¢0) 7185 (66¢8)
) 520 (34¢5) 640 (36¢0) 3574 (33¢2)
68 (4¢3) 19 (1¢0) 1073 (9¢4)
) 368 (23¢4) 376 (20¢4) 2767 (24¢2)
47 (3¢0) 23 (1¢3) 371 (3¢2)
145 (9¢2) 63 (3¢4) 908 (8¢0)
) 530 (33¢7) 609 (33¢0) 3469 (30¢4)
18 (1¢1) 13 (0¢7) 121 (1¢1)
15 (1¢0) 8 (0¢4) 122 (1¢1)
) 383 (24¢3) 733 (39¢8) 2578 (22¢6)
Table 2
Baseline characteristics of COPD Patients starting maintenance therapy, therapy initiated and appropriateness of this therapy according to the GOLD 2019 Report. *To avoid
unintentional disclosure and to preserve conﬁdentiality, cell counts <5 are reported as <5.
Baseline characteristics Group A Group B Group C Group D Overall
N = 316 N = 199 N = 110 N = 74 N = 699
% of patients in group 45¢2 28¢5 15¢7 10¢6 
Mean age (y)(SD) 67¢9 (9¢9) 69¢8 (11¢7) 68¢8 (9¢6) 70¢6 (10¢3) 68¢9 (10¢5)
Men % 59¢5 58¢3 58¢2 59¢5 58¢9
Non-missing, % 314 (99¢4) 199 (100) 109 (99¢1) 74 (100) 696 (99¢6)
Mean BMI (SD) 27¢3 (5¢9) 28¢2 (6¢3) 27¢2 (5¢1) 27¢6 (6¢2) 27¢6 (5¢9)
Non-missing, % 315 (99¢7) 199 (100) 110 (100) 74 (100) 698 (99¢9)
Current smokers n (%) 147 (46¢7) 89 (44¢7) 50 (45¢5) 35 (47¢3) 315 (45¢1)
Ex-smokers n (%) 143 (45¢4) 93 (46¢7) 48 (43¢6) 37 (50¢0) 327 (46¢9)
Non-smokers n (%)(%) 25 (7¢9) 17 (8¢6) 12 (10¢9) <5* 56 (8¢0)
Asthma (%) 37 (11¢7) 20 (10¢1) 18 (16¢4) 6 (8¢1) 81 (11¢6)
Non-missing, % 314 (99¢4) 199 (100) 109 (99¢1) 73 (97¢3) 695 (99¢4)
Mean FEV1 (%pred)(SD) 66¢6 (18¢7) 57¢6 (20¢3) 64¢3 (19¢4) 59¢1 (22¢9) 62¢9 (20¢1)
Gold 1: 80% 64 (21¢0) 22 (11¢6) 19 (18¢4) 12 (16¢9) 117 (17¢5)
Gold 2: 5079% 187 (61¢3) 99 (52¢4) 63 (61¢2) 33 (46¢5) 382 (57¢2)
Gold 3: 3049% 50 (16¢4) 56 (29¢6) 17 (16¢5) 19 (26¢8) 142 (21¢3)
Gold 4: <30% <5 12 (6¢4) <5 7 (9¢8) 27 (4¢0)
Mean exacerbations/y (SD) 0¢3 (0¢5) 0¢4 (0¢5) 2¢6 (1¢0) 2¢7 (1¢4) 1¢4 (0¢9)
Exacerbations/y in previous year 0 225 (71¢2) 124 (62¢3) 0 (0) 0 (0) 349 (49¢9)
1 91 (28¢8) 75 (37¢7) 0 (0) 0 (0) 166 (23¢7)
2 0 (0) 0 (0) 110 (100¢0) 74 (100¢0) 184 (26¢3)
Mean mMRC (SD) 0¢7 (0¢5) 2¢3 (0¢6) 0¢8 (0¢4) 2¢3 (0¢5) 2¢4 (0¢6)
Non-missing, % 291 (92¢1) 187 (93¢7) 102 (92¢7) 68 (91¢9) 648 (92¢7)
Mean Eosinophil count (109/L) (SD) 0¢2 (0¢2) 0¢2 (0¢2) 0¢3 (0¢2) 0¢2 (0¢1) 0¢3 (0¢2)
Eosinophil count< 0¢30£ 109/L 194 (66¢7) 118 (63¢1) 60 (58¢8) 49 (72¢1) 421 (65¢0)
Eosinophil count 0¢30£ 109/L 97 (33¢3) 69 (36¢9) 42 (41¢2) 19 (27¢9) 227 (35¢0)
Therapy initiated n (%)
LAMA only 155 (49¢1) 100 (50¢3) 44 (40¢0) 35 (47¢3) 334 (47¢8)
LABA only 19 (6¢0) 7 (3¢5) 6 (5¢4) <5 36 (5¢1)
ICS only 50 (15¢8) 18 (9¢0) 16 (15¢6) <5 87 (12¢5)
ICS + LABA 79 (25¢0) 59 (29¢7) 39 (35¢5) 20 (27¢0) 197 (28¢2)
ICS + LAMA <5 0 (0) 0 (0) <5 5 (0¢7)
LAMA + LABA <5) <5 <5 0 (0) 7 (1¢0)
ICS + LABA + LAMA 8 (2¢5) 11 (5¢5) <5 10 (13¢5) 33 (4¢7)
Treatment according to Gold 2019 Report (%)
Under-treatment 0 (0) 0 (0) 22 (20¢0) 7 (9¢5) 
Appropriate treatment 174 (55¢1) 107 (53¢8) 44 (40¢0) 57 (77¢0) 
Over-treatment 142 (44¢9) 92 (46¢2) 44 (40¢0) 10 (13¢5) 
Number of overtreated patients with coexistent asthma 28 (19¢7) 18 (19¢6) 10 (22¢7) <5 
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and across cohorts, with approximately two thirds of the patients
having counts below 300£ 109/L.
Over half of established patients were on therapy containing ICS
and a quarter were on LAMA alone, with no differences between the
GOLD groups. More established patients in group D were on triple
therapy (39¢8%) than those in groups B (26¢2%) and C (24¢3%), and tri-
ple therapy was only used in 13¢7% of patients in group A (Table 1).
In patients initiating therapy, LAMA monotherapy was the com-
monest treatment in all groups, with ICS containing therapy used in
less than 50% of the patients. Very few patients in groups A, B & C
were started on triple therapy, but it was the ﬁrst maintenance ther-
apy used in 13¢5% of patients in group D.
3.2. Change of GOLD Groups Over 2 years
In both cohorts, the overall proportion of patients in each GOLD
group was similar in 2014 and 2016 (cohort 1: Kappa: 0¢33, 95% CI:
0¢320¢35; cohort 2: Kappa: 0¢03, 95% CI: 0¢010¢07), but there had
been substantial movement of individual patients (Fig. 2). In both
cohorts, over half of the patients in groups A and B at baseline stayed in
these groups, but over 20% of patients in group B at baseline in both
cohorts moved into group A (i.e. became less symptomatic). Over the
two years 41¢2% of established COPD patients categorised as meeting
the criteria for group D in 2014 moved to groups A or B on the basis of
having had fewer exacerbations. 52¢7% COPD patients in group Dstarted on maintenance therapy in 2014 moved to groups A or B, with
only 36¢5% staying in group D over 2 years.
3.3. Appropriateness of Therapy
In established COPD patients there appeared to be substantial over-
treatment of patients with blood eosinophil counts <100 and those
with higher eosinophil counts with mMRC<2 and fewer than 2 exacer-
bations in the previous year (Table 3). The medications prescribed to
patients judged as over-treated are shown in Appendix table S4. In the
majority of cases over-treatment was due to the inappropriate use of
ICS containing therapies. 2030% of the patients who appeared over-
treated according to COPD recommendations had current asthma,
which may explain the use of ICS. Symptomatic patients with mMRC of
2 or more and those with frequent exacerbations appeared under-
treated irrespective of eosinophil counts. For patients initiating therapy
(cohort 2), many patients in groups A, B and C appeared to be over-
treated, although again 20% of the patients who appeared over-treated
had current asthma, some patients in groups C & D were undertreated
and some in group D were overtreated having been started on triple
therapy as their initial therapy (Table 4).
3.4. Comorbid Conditions
Diabetes, cardiovascular disease and osteoporosis were the most
common comorbidities in patients in all GOLD groups in both cohorts
Fig. 1. Patient selection.
36 D.M.G. Halpin et al. / EClinicalMedicine 14 (2019) 3241(Table 5 & Appendix, tables S5 & S6). There was no difference in the
prevalence of comorbidities between the two cohorts of COPD
patients, except for osteoporosis which was less common in patients
initiating therapy (4¢3% vs. 7¢7%; OR: 0¢54 (95%CI 0¢370¢78)
p = 0¢001) (Table 5).
Most comorbidities were more common in the established COPD
patients than in patients who did not have COPD matched for age,
sex and smoking history (Appendix, table S7), whereas cardiovascu-
lar comorbidities, anxiety/depression, rhinitis and gastroesophageal
reﬂux were more common in COPD patients starting maintenance
therapy than in their matched controls (Appendix, table S7).3.5. Exacerbations
The mean exacerbation rates during follow-up for patients in each
GOLD group for established patients and those initiating therapy is
shown in Table 6. For the established patients (cohort 1) the mean
rates for patients in groups A and B were higher and in groups C and
D were lower during follow-up than in the year prior to ID (Table 1).
Patients in GOLD groups B, C & D had signiﬁcantly higher exacerba-
tion rates during follow-up than patients in group A (RRs:
1¢423¢69) (Table 6).
For patients initiating maintenance therapy (cohort 2) exacerba-
tion rates were higher during follow-up than in the year prior to ID
for patients in groups A & B, but lower during follow up for patients
in groups C & D (Table 1). Patients initiating therapy in GOLD groups
B, C & D again had signiﬁcantly higher exacerbation rates during fol-
low-up than patients in group A (RRs: 1¢602¢90) (Table 6). The dis-
tribution and mean exacerbation rate per year during the follow up
period of COPD patients initiating therapy in each GOLD group, cate-
gorised by appropriateness of therapy according to the 2019 GOLD
Report, are shown in Appendix table S9. Exacerbation rates appeared
slightly higher in people who were categorised as over-treated in
groups A, B & C and also higher in those that appeared under-treated
in groups C & D but the numbers of patients in each category were
small and the differences were not tested statistically.3.6. Pneumonia
Pneumonia in the year prior to ID was signiﬁcantly more commonly
recorded in established patients with COPD than in matched controls,
occurring in 1¢1% of COPD patients and in 0¢5% of controls (OR: 2¢20 95%
CI 1¢772¢75), and in 1¢3% of patients startingmaintenance therapy com-
pared with 0¢1% of matched controls (OR: 17¢98 95%CI 3¢8983¢18). In
established COPD patients the proportion of patients in each GOLD group
diagnosed with pneumonia during follow-up was 1¢5% in group A and
3¢23¢3% in groups B-D. However, no statistical differences between the
GOLD groups and the rate of pneumonia was observed (data not shown).
3.7. Escalation/De-escalation of Therapy
Fig. 3 shows the proportion of patients initiating therapy
(cohort 2) who had their therapy escalated, de-escalated, switched or
left unchanged over the two years of follow-up by initial GOLD group.
Patients in group B were slightly more likely to have their treatment
switched or escalated than patients in other groups (table S10).
Appendix table S11 shows the appropriateness of maintenance ther-
apy after two years, assessed according to the recommendations for ini-
tial therapy for the GOLD group in 2014. In patients in group A there was
an equal tendency both to increase treatment in approximately a quarter
of those appropriately treated at baseline, and de-escalate in those over
treated at baseline. A similar pattern was seen in group B, but 11% of
patients who were over-treated at baseline were de-escalated to therapy
that appeared to leave them under-treated. In group C half of the patients
under-treated at baseline remained under-treated at follow-up, whilst
most who were initially over-treated appeared appropriately treated at
follow-up. In group D patients who were under-treated initially were
either appropriately treated at follow-up (43%) or over-treated (57%),
most whowere appropriately or over-treated remained so.
4. Discussion
This study shows that nearly half of the COPD patients initiating ther-
apy were in GOLD group A but nearly 10% were in GOLD group D.
Fig. 2. Alluvial diagrams showingmovement of patients between GOLD groups between
2014 and 2016 (A) Established COPD patients (B) COPD Patients initiating therapy.
Table 3
Appropriateness of therapy in established COPD patients on maintenance therapy in 2014 ac
frequency and blood eosinophil counts at ID (cohort 1). (To avoid unintentional disclosure an
Treatment according to Gold 2019 report Baseline C
mMRC< 2
<2 exacer
Eos< 100 N =
Under-treatment (%) 0
Appropriate treatment (%) 159
Over-treatment (%) 131
Number of overtreated patients with coexistent asthma (%) 24 (
Eos 100300 N =
Under-treatment (%) 0
Appropriate treatment (%) 1479
Over-treatment (%) 1383
Number of overtreated patients with coexistent asthma (%) 354
Eos> 300 N =
Under-treatment (%) 0
Appropriate treatment (%) 691
Over-treatment (%) 832
Number of overtreated patients with coexistent asthma (%) 233
Missing Eos (% of group)) N = 37
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that of the patients initiating therapy. The baseline demographic and dis-
ease characteristics of the patients in our study are similar to those previ-
ously reported for patients in the UK and internationally [3,6]. The fact
that nearly half of patients initiating maintenance therapy were current
smokers is concerning, considering that smoking cessation is the single
most important intervention for all COPD patients. In both cohorts there
was a striking similarity in the distribution of lung function impairment
across the GOLD groups, with GOLD stage 2 being the most common
abnormality. As would be expected there was a trend towards worse
lung function in patients in the more symptomatic groups B & D, but it
was surprising that there were still more patients in these groups in
both cohorts that had an FEV1 80% predicted (i.e. GOLD stage 1) than
those with an FEV1< 30% predicted (i.e. GOLD stage 4).
Comorbidities were common in both cohorts and were more com-
mon in the cohorts than matched controls who did not have COPD.
Nearly 20% of established patients and over 10% of patients initiating
therapy had a diagnosis of current asthma. Apart from osteoporosis,
comorbidities were not more common in patients with established
COPD disease than in those initiating therapy. This may suggests that
most comorbidities share common risk factors with COPD rather than
being a consequence of having developed COPD, but the prevalence of
osteoporosis may have been increased both by the likely more long-
standing inactivity of established patients, systemic effects of COPD
and steroid therapy [14]. Anxiety or depressionwere recorded as being
present in approximately 1 in 5 patients with established COPD and in
a similar proportion of patients initiating maintenance therapy. The
recognition and management of these comorbidities is important as
they are associated with increased levels of symptoms, a greater likeli-
hood of being hospitalised, poor compliance with therapy and less suc-
cess with smoking cessation strategies [1518].
Assessing patients using the GOLD groups did identify patients at
greater risk of exacerbations in both cohorts. The risk patients in group D
compared to group Awas greater in the established patients than in those
initiating therapy. This probably reﬂects the fact that established patients
were assessed as being in GOLD group D (i.e. having frequent exacerba-
tions) while already on therapy, whereas patients initiating therapy may
had greater opportunity for treatment to reduce the risk of exacerbations.
In both cohorts there was considerable change in symptoms and
risk of exacerbations over two years, leading to potential reclassiﬁca-
tion of patients. However, in both cohorts nearly two thirds of patients
in group A and half of the patients in group B remained in the same
group. Group C was the least stable with only 27.2% of establishedcording to recommendations of the GOLD 2019 Report, based on dyspnea, exacerbation
d to preserve conﬁdentiality, cell counts <5 are reported as <5.
haracteristics
mMRC 2
bations 2 exacerbations <2 exacerbations 2 exacerbations
290 N = 93 N = 197 N = 96
(0) 36 (38¢7) 77 (39¢1) 27 (28¢1)
(54¢8) 0 (0) 5 (2¢5) 0 (0)
(45¢2) 57 (61¢3) 115 (58¢4) 69 (71¢9)
18¢3) 16 (28¢1) 25 (21¢7) 15 (21¢7)
2862 N = 893 N = 1714 N = 1040
(0) 673 (75¢4) 743 (43¢4) 637 (61¢3)
(51¢7) 220 (24¢6) 971 (56¢6) 403 (38¢7)
(48¢3) 0 (0) 0 (0) 0 (0)
(25¢6) 0 (0) 0 (0) 0 (0)
1523 N = 520 N = 891 N = 640
(0) 210 (40¢4) 376 (42¢2) 369 (57¢7)
(45¢4) 310 (59¢6) 515 (57¢8) 271 (42¢3)
(54¢6) 0 (0) 0 (0) 0 (0)
(28¢0) 0 (0) 0 (0) 0 (0)
8 (7¢5) N = 67 (4¢3) N = 135 (4¢6) N = 68 (3¢7)
Table 4
Appropriateness of therapy prescribed in patients initiating maintenance therapy in 2014 according to recommendations for initial therapy in the GOLD 2019 Report (cohort 2).
(To avoid unintentional disclosure and to preserve conﬁdentiality, cell counts <5 are reported as <5).
Group A Group B Group C Group D
N = 316 N = 199 N = 110 N = 74
Under-treatment (%) 0 (0) 0 (0) 22 (20.0) 7 (9.5)
Appropriate treatment (%) 174 (55.1) 107 (53.8) 44 (40.0) 57 (77.0)
Over-treatment (%) 142 (44.9) 92 (46.2) 44 (40.0) 10 (13.5)
Number of overtreated patients with coexistent asthma (%) 28 (19.7) 18 (19.6) 10 (22.7) <5
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ing in the group after 2 years whilst most moved into the low exacer-
bation risk groups A and B. One third of patients initiating therapy
remained in GOLD group D after 2 years, but many patients moved to
a lower exacerbation risk group, possibly as a result of effective man-
agement. Similar changes have been reported in the Eclipse cohort
which predominantly contained established patients attending outpa-
tient clinics in secondary care [19].
The therapy initiated in patients in groups A, B & C differed from
that currently recommended in the GOLD report [2] and from the
therapy recommended by GOLD at the time [20]. At the time that
these patients were being managed, clinicians in the UK were
increasingly being encouraged by payors to use the GOLD recommen-
dations rather than following the NICE guidelines as the latter had
not been updated since 2010 [21]; however, not all clinicians would
have been aware of the GOLD recommendations or encouraged to
follow them. Approximately 20% of patients assessed as being over-
treated had asthma as well as COPD and in these patients the use of
ICS would have been justiﬁed and therefore they were appropriately
treated but this still leaves a signiﬁcant number of patients who were
overtreated, predominantly with ICS. Despite these caveats, compari-
son of the therapy prescribed with the current GOLD recommenda-
tions and its correlation with exacerbation rates is of interest. The
2019 GOLD Report emphasises that the assessment of symptoms and
risk of exacerbations originally should only be used as a basis for
determining initial therapy and is not designed for reassessing
patients per GOLD group during follow-up.
In our analysis, a substantial proportion of patients initiating ther-
apy in groups A & B were over-treated and 20% of patients in group C
were under-treated. By deﬁnition COPD patients in this cohort of ini-
tiators all received maintenance therapy, so we cannot comment on
the prevalence of patients with COPD who were experiencing symp-
toms or had a history of exacerbations but who did not receive any
treatment. However, among the established COPD patients there
appeared to be under-treatment of symptomatic patients and those
continuing to exacerbate suggesting these factors were not being
considered when patients were reviewed, and over-treatment ofTable 5
Prevalence of comorbid conditions in COPD patients initiating maintenance therapy (cohort 2) a
cohort 2 vs. cohort 1. *Active at the index date, (To avoid unintentional disclosure and to preserv
Co-morbidity ever or in the year before the index
date, n (%)
COPD patients initiating thera
(Cohort 2)
N = 699
Diabetes mellitus 103 (14¢7)
Hypertension 303 (43¢4)
Cardiovascular disease* 71 (10¢2)
Heart failure* 12 (1¢7)
Ischaemic heart disease 128 (18¢3)
Sleep apnoea <5
Nasal polyps <5
Osteoporosis 30 (4¢3)
Chronic Kidney Disease Stage IV-V 14 (2¢0)
Anxiety/Depression* 136 (19¢5)
Eczema* 22 (3¢2)
Rhinitis* 48 (6¢9)
Gastroesophageal reﬂux disease* 92 (13¢2)people with low eosinophil counts. At the time these patients were
being treated the blood esosinophil count had not been recom-
mended as a factor to guide maintenance therapy, but these results
suggest that if it had been used as GOLD now recommend when
reviewing therapy, it may have been possible to de-escalate therapy
in a large number of patients. People with low levels of symptoms or
low exacerbation rates also appeared over-treated but may have
actually been successfully treated.
Over 40% of patients initiating maintenance therapy in groups A
and B were prescribed an ICS containing therapies, with substantial
initiation of ICS monotherapy. Our ﬁndings are in line with previous
studies analysing adherence to recommendations on the management
of COPD, although most of these looked at the appropriateness of ther-
apy in patients classiﬁed into groups A-D whilst on therapy rather
than their GOLD group at initiation of therapy [36]. The adherence to
guideline recommendations in this study may represent a ‘best case’
scenario given the fact that considerable rigour had been used to diag-
nose COPD using spirometry and the likelihood that this would trans-
late to considered therapy choices. Previous studies have examined
the possible reasons underlying the difference between real-life prac-
tice and evidence-based treatment recommendations. Poor familiarity
has been found to be associated with nonadherence to the previous
recommendations on ICS and long-acting bronchodilators [22], and
primary care physicians who had difﬁculty assessing response to ther-
apy were less likely to adhere to recommendations on long-acting
bronchodilator use [23]. However, in our analysis the mean exacerba-
tion rate per year appeared higher in people who were categorised as
over-treated in groups A, B & C. Similar patterns have been reported in
an analysis of prescribing at a Veterans Administration Medical Center
in the USA [24]. This may suggest that additional clinical features asso-
ciated with an increased risk of exacerbations led the managing clini-
cians to prescribe therapy which was at variance with the GOLD
recommendations, but perhaps appropriate for that individual.
There were changes in therapy in the patients initiating mainte-
nance therapy over the two years of follow-up, but most commonly
treatment was left unchanged and for patients in groups A and B this
meant that many remained over-treated. There was evidence ofnd established COPD patients (cohort 1) and odds ratio for prevalence of comorbidities in
e conﬁdentiality, cell counts <5 are reported as <5.
py Established COPD patients
(Cohort 1)
OR 95% (CI)
Cohort 2 vs¢ Cohort 1
p-Value
N = 11,409
1801 (15¢8) 0¢92 (0¢741¢14) 0¢46
5359 (47¢0) 0¢86 (0¢741¢01) 0¢06
1216 (10¢7) 0¢95 (0¢741¢22) 0¢68
162 (1¢4) 1¢21 (0¢672¢19) 0¢52
2154 (18¢9) 0¢96 (0¢791¢17) 0¢71
43 (0¢4) 0¢38 (0¢052¢75) 0¢34
24 (0¢2) 1¢36 (0¢325¢77) 0¢67
874 (7¢7) 0¢54 (0¢370¢78) 0¢001
247 (2¢2) 0¢92 (0¢541¢59) 0¢77
2326 (20¢4) 0¢94 (0¢781¢14) 0¢55
385 (3¢4) 0¢93 (0¢601¢44) 0¢75
903 (7¢9) 0¢86 (0¢641¢16) 0¢32
1763 (15¢5) 0¢83 (0¢661¢04) 0¢10
Table 6
Mean annual exacerbation rates over 2 years in established COPD patients and those
initiating maintenance therapy in 2014 by GOLD group at baseline. SD = standard devi-
ation; RR = rate ratio; CI = conﬁdence interval.
GOLD group
in 2014
Exacerbation rate per year per GOLD group
N Mean
(SD)
RRcrude (95% CI) RRage and sex-adjusted (95%
CI)
Established COPD patients (Cohort 1)
Group A 5053 0¢7 (0¢9) Reference Reference
Group B 2938 0¢9 (1¢0) 1¢41 (1¢341¢48) 1¢42 (1¢341¢49)
Group C 1574 1¢9 (1¢7) 2¢89 (2¢733¢06) 2¢87 (2¢713¢04)
Group D 1844 2¢4 (1¢9) 3¢71 (3¢523¢91) 3¢69 (3¢503¢89)
COPD patients initiating therapy (Cohort 2)
Group A 316 0¢6 (0¢8) Reference Reference
Group B 199 1¢0 (1¢2) 1¢61 (1¢301¢99) 1¢60 (1¢291¢97)
Group C 110 1¢5 (1¢6) 2¢68 (2¢113¢40) 2¢68 (2¢113¢41)
Group D 74 1¢8 (1¢9) 2¢93 (2¢243¢84) 2¢90 (2¢213¢81)
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sidered under-treated initially in groups C and D, suggesting that
clinicians had reviewed the patients and adjusted therapy based on
continued symptoms or exacerbations. It was not possible to assess
the appropriateness of changes in in established COPD patients
according to the recommendations for follow-up in the GOLD 2019
Report as information was not available in the database about indi-
vidual's treatable traits at the time of review.
4.1. Strengths and Limitations of the Study
Our study has several strengths including the large sample size,
completeness of follow-up and the robustness of the COPD diagnosis
in OPCRD which is based on symptoms and spirometry. OPCRD is a
well-maintained database which is used frequently for observational
research and it contains information which is prospectively collected,
and not subjected to recall bias. The dataset draws from aFig. 3. Percentage of patients initiating maintenance therapy in each GOLD group in 2014 w
years of follow-up.geographically and socioeconomically diverse population, and there-
fore we believe that the study results reﬂect routine clinical practice
in the UK and show the true distribution of UK patients among the
GOLD groups, and their demographic and disease characteristics. It
also shows the differences between real-world prescribing patterns
in the UK and guideline recommendations.
Potential study limitations include the fact that the data set
reﬂects the demographics of patients and clinical practice in the UK
only. Furthermore, to be included in the study patients had to have
an mMRC score and the number of exacerbations recorded in their
medical notes in 2014, 2015 and 2016 and may not therefore be
fully representative of all patients with COPD. Different guidelines,
such as the NICE COPD guideline may have inﬂuenced management
and availability of medication and initiatives by payors may also
have inﬂuenced prescribing, for example inhalers containing LABA/
LAMA were only launched in the UK in late 2014 [25]. Patients' clas-
siﬁcation into the GOLD groups was based solely on their mMRC
scores as these are routinely recorded in UK primary care practice;
however, some clinicians may have used CAT scores to assess
patients and make treatment decisions. CAT scores are not system-
atically recorded in all patients. It is also not possible to determine if
patients were adherent with their therapy and thus the presence of
symptoms or occurrence of exacerbations in patients on treatment
may reﬂect under-treatment or poor adherence to prescribed medi-
cations, or both.
In summary, this analysis indicates that the majority of patients are
not at high risk of exacerbations and that smoking and comorbidities
are common at the time patients initiate maintenance therapy. Many
patients in GOLD groups A and B are over-treated when compared to
the GOLD recommendations, in particular they are prescribed ICS alone
or in combination with a LABA as their ﬁrst maintenance therapy. Many
patients remained symptomatic and continued to have exacerbations
despite treatment, but there was evidence that therapies were escalated
and de-escalated in response to this; however many remained over-
treated and continued work is needed to improve clinicians assessment
and management of patients with COPD using dissemination methodsho had their therapy escalated, de-escalated, switched or left unchanged over the two
40 D.M.G. Halpin et al. / EClinicalMedicine 14 (2019) 3241more likely to change behaviour [26] in order to limit the risks and costs
associated with under-treatment and over-treatment and to improve
patient outcomes.
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Appendix A
A.1. Data Requirements and Data Extracted From OPCRD
To estimate the patient characteristics in each cohort, and to pre-
vent user bias in the study of patients in cohort 2, every patient had
to be registered with a general practitioner (GP) for at least one year
before the ID. Patients had to have had continuous medical record
data between January 1, 2014 and December 31, 2016, to have had at
least one record of a modiﬁed MRC (mMRC) dyspnoea score per yearbetween January 1, 2014 and December 31, 2016, and to have had at
least one record of exacerbation frequency (including none) per year
between January 1, 2013 and December 31, 2015. Patients were
excluded if they had a previous diagnosis of other lower respiratory
disease other than COPD, asthma, or bronchitis at any time.
For eligible patients the following data were extracted from the
OPCRD: age at ID; sex; body mass index (BMI, kg/m2) within 5 years
prior to ID; smoking status (categorised as never smokers, current
smokers, former smokers); FEV1% predicted (categorised by GOLD
stage: GOLD 1: 80, GOLD 2: 5079, GOLD 3: 3049, GOLD 4: <30);
mMRC dyspnoea score (categorised as: 01 and 2); blood eosinophil
count (categorised as 0.30£ 109/L (high) and< 0.30£ 109/L (low));
prescription of respiratory drugs; the presence of comorbidities
recorded as active problems in the year prior to the ID; and whether
or not patients had a diagnosis of pneumonia in the year prior to the
ID. Based on their mMRC score and history of exacerbations in the pre-
vious year, patients within each cohort were then classiﬁed by the
GOLD 2017 classiﬁcation scheme as GOLD group A, B, C or D in the
year 2014 and 2016 [1].
COPD exacerbations were deﬁned as the occurrence of the follow-
ing events:
a. Unscheduled hospital admission with acute COPD exacerbation
as the primary diagnosis AND/OR,
b. Unscheduled COPD-related accident & emergency (A&E) atten-
dance AND/OR,
c. An acute course of oral corticosteroid AND/OR.
d. Antibiotics prescribed with evidence of a lower respiratory con-
sultation.
When oral corticosteroids and antibiotics were prescribed during
a routine respiratory review (mMRC and a prescription of oral corti-
costeroids and/or antibiotics at the same day) the prescription of
both of these drugs was not be included in the algorithm for estimat-
ing the number of exacerbations. An exacerbation within 14 days
from a previous one was considered to belong to the same event.
A.2. Complementary Analysis on Comorbidities
We compared the comorbidities of the patients in cohort 2 with
the ones from cohort 1 by conducting a logistic regression to derive
odds ratios (ORs) and 95% CIs. We also examined the prevalence of
comorbid conditions in a general population to determine whether
the overall prevalence of comorbidities was higher in patients with
established COPD. For each patient with COPD we randomly selected
up to four controls matched by age (§2 years), sex and smoking sta-
tus (never/ever/ex-smoker), and randomly selected from the popula-
tion of patients at risk for COPD at the index date of the patient with
COPD. We then assessed the association between the prevalence of
comorbid conditions and having COPD using conditional logistic
regression.
Appendix B. Supplementary Data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.eclinm.2019.07.003.
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